RTOG-1016

Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

Principal Investigator

Andy Trotti

Status

Disease Site

Head and Neck [HN] Head and Neck

Phase

III

Developmental Therapeutics

No

Primary Objective

To determine whether substitution of cisplatin with cetuximab will result in comparable 5-year overall survival

Closed to both Step 1 and Step 2 Registration.

Note: If your site is in possession of an RTOG 1016 study iPad, contact Robert Pickard at rtog1016@osumc.edu or 1-614-292-0875 to make arrangements for the return of the iPad.

The quality of life (QOL) component met its accrual objective (400 patients) and closed to accrual on 2/28/13.

Patient Population

Squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); stage T1-2, N2a-3, or T3-4 any N; patient tumor must be p16 positive

 

 

 

Target Accrual

849